SKB264 Innovative Cancer Antibody Drug Conjugate Clinical Trials Efficacy Insight
19. September 2024 07:34 ET
|
KuicK Research
Delhi, Sept. 19, 2024 (GLOBE NEWSWIRE) -- SKB264, also known as MK-2870, is an innovative antibody-drug conjugate (ADC) targeting TROP2, currently being developed by Kelun Biotech in partnership...